Medicines/Item |
Section |
Status |
Link Name / Link URL |
Abiraterone |
08.03.04.02 |
Restricted Use
|
NICE TA259: Abiraterone for treating metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen |
Acitretin |
13.05.02 |
Restricted Use
|
NICE CG153: Psoriasis - assessment and management |
Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severeley active ulcerative colitis after failure of conventional therapy |
Adalimumab |
01.05.03 |
Restricted Use
|
TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA486 Aflibercept for treating choroidal neovascularisation |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA486 Aflibercept for treating choroidal neovascularisation |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA294 Aflibercept solution for injection for treating wet age‑related macular degeneration |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
Aflibercept |
11.08.02 |
Formulary
|
NICE TA346 Aflibercept for treating diabetic macular oedema |
Alirocumab |
20.01 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Alitretinoin |
13.05.01 |
Restricted Use
|
NICE guidelines - Alitretinoin for chronic eczema |
Apixaban |
02.08.02 |
Formulary
|
NICE guidance: Apixaban for the prevention of VTE after total hip or knee replacement in adults |
Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466 Baricitinib for moderate to severe rheumatoid arthritis |
benralizumab |
03.01 |
Restricted Use
|
NICE TA565 |
Brodalumab |
13.05.02 |
Formulary
|
NICE TA511 - Brodalumab for treating moderate to severe plaque psoriasis |
Calcipotriol 50micrograms/g with Betamethasone 0.05% |
13.05.02 |
Formulary
|
NICE CG153: The assessment and management of psoriasis |
Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
Ciclosporin |
13.05.03 |
Formulary
|
NICE CG153: Psoriasis - assessment and management |
Ciclosporin 1mg/mL Eye Drops |
11.08.01 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
Clostridium Botulinum neurotoxin type A |
04.09.03 |
Formulary
|
NICE TA605; Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
Colesevelam |
02.12 |
Restricted Use
|
NICE evidence review: Colesevelam for bile acid malabsorption |
Collagenase clostridium histolyticum |
10.03.01 |
Formulary
|
NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA 327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for the treatment and secondary prevention of stroke and systemic embolism in atrial fibrilation |
Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
Dexamethasone |
11.04.02 |
Formulary
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis |
Donepezil Hydrochloride |
04.11 |
Restricted Use
|
NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
Dulaglutide |
06.01.02.03 |
Formulary
|
NICE ESNM59: Dulaglutide for Type 2 Diabetes |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and preventing DVT and PE |
Edoxaban |
02.08.02 |
Formulary
|
NICE TA355: Edoxaban for preventing stroke and embolism in people with non-valvular AF |
Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic perpura |
Eluxadoline |
01.04.02 |
Non Formulary
|
NICE TA471 - Eluxadoline (Truberzi) for treating irritable bowel syndrome with diarrhoea in adults |
Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes |
Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
Etanercept |
13.05.03 |
Restricted Use
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etanercept |
13.05.03 |
Restricted Use
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etanercept |
10.01.03 |
Restricted Use
|
TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etanercept |
10.01.03 |
Restricted Use
|
- TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Etelcalcetide |
06.06.01 |
Restricted Use
|
NICE TA448 Etelcalcetide for treating secondary hyperparathyroidism |
Evolocumab |
20.01 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
Fluocinolone acetonide |
11.04.01 |
Formulary
|
NICE TA301 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
Fluocinolone acetonide |
11.04.01 |
Formulary
|
NICE TA613 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy |
Fluocinolone acetonide |
11.04.01 |
Formulary
|
NICE TA590 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631 Fremanezumab for preventing migraine |
Fulvestrant |
08.03.04.01 |
Restricted Use
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
Galantamine |
04.11 |
Restricted Use
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
Galantamine |
04.11 |
Restricted Use
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
Galcanezumab |
04.07.04.02 |
Formulary
|
NICE TA659 Galcanezumab for preventing migraine |
Golimumab |
01.05.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
Guselkumab |
13.05.03 |
Formulary
|
NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis |
Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA 429 |
Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA502 |
Idelalisib 100mg and 150mg tablets |
20.01 |
Restricted Use
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia |
Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severeley active ulcerative colitis after failure of conventional therapy |
Isosorbide Mononitrate |
02.06.01 |
Formulary
|
NICE CG126: Stable angina |
Ivabradine |
02.06.03 |
Restricted Use
|
NICE CG126: Stable angina |
Ivabradine |
02.06.03 |
Restricted Use
|
NICE TA267: Ivabradine for treating chronic heart failure |
Ixekizumab 80mg solution for injection |
13.01 |
Formulary
|
NICE TA442 - Ixekizumab for treating moderate to severe plaque psoriasis |
lanadelumab |
13.05.03 |
Restricted Use
|
NICE TA606 Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606) |
Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
Lesinurad |
10.01.04 |
Non Formulary
|
NICE TA506 Lesinurad for treating chronic hyperuricaemia in people with gout |
Linaclotide |
01.06.07 |
Restricted Use
|
NICE ESNM16: Irritable bowel syndrome with constipation in adults: linaclotide |
Liraglutide |
06.01.02.03 |
Formulary
|
NICE guidance 28 - Type 2 dibetes in adults: management |
Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318 Lubiprostone for treating chronic idiopathic constipation |
Memantine Hydrochloride |
04.11 |
Formulary
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
Methotrexate |
13.05.03 |
Restricted Use
|
NICE CG153: Psoriasis - assessment and management |
Naloxegol oxalate |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid-induced constipation |
Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443 Obeticholic acid for treating primary biliary cholangitis |
Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278: Omalizumab for treating severe persistent asthma |
patiromer |
09.02.01.01 |
Formulary
|
NICE TA623 Patiromer for treating hyperkalaemia |
Pemetrexed |
08.01.03 |
Formulary
|
TA190 (updated from June 2010) - Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
Pentosan Polysulfate Sodium 100mg capsules |
07.04.03 |
Restricted Use
|
NICE TA610 Pentosan polysulfate sodium for treating bladder pain syndrome |
PENTOSAN POLYSULPHATE capsules |
20 |
Restricted Use
|
NICE TA610 |
Pomalidomide |
08.02.04 |
Restricted Use
|
NICE TA338: Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib |
Prucalopride |
01.06.07 |
Restricted Use
|
NICE TA211: Prucalopride for constipation in women |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA274 Ranibizumab for treating diabetic macular oedema |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
Ranibizumab |
11.08.02 |
Formulary
|
NICE TA283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Stable angina |
Reslizumab |
03.04.02 |
Restricted Use
|
NICE TA479 Reslizumab for treating severe eosinophilic asthma |
Rifaximin 550mg tablets |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE guidance: Rivaroxaban for the treatment of deep vein thrombosis and the prevention of recurrent DVT and PE |
Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
Rivastigmine |
04.11 |
Restricted Use
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
Roflumilast |
03.03.03 |
Formulary
|
TA461 - Roflumilast for treating chronic obstructive pulmonary disease |
Sacubitril/valsartan |
02.05.05.02 |
Formulary
|
TA 388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
Sarilumab |
10.01.03 |
Restricted Use
|
NICE TA485 Sarilumab for moderate to severe rheumatoid arthritis |
Secukinumab |
20.01 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
Secukinumab |
20.01 |
Formulary
|
NICE TA350:Secukinumab for treating moderate to severe plaque psoriasis |
Semaglutide pre filled pen |
06.01.02.03 |
Formulary
|
Type 2 diabetes in adults: management |
Sodium Zirconium Cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599 Sodium zirconium cyclosilicate for treating hyperkalaemia |
Teriparatide |
06.06.01 |
Restricted Use
|
NICE TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
Ticagrelor |
02.09 |
Restricted Use
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518 - Tocilizumab for treating giant cell arteritis |
Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518 - Tocilizumab for treating giant cell arteritis |
Tofacitinib |
10.01.03 |
Restricted Use
|
NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis |
Tofacitinib |
10.01.03 |
Restricted Use
|
Tofacitinib severely active ulcerative colitis TA547 |
Tolvaptan |
06.05.02 |
Restricted Use
|
NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease |
Trastuzumab emtansine |
08.01.05 |
Restricted Use
|
TA458 - Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
Ustekinumab |
13.05.03 |
Formulary
|
- TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
Ustekinumab |
13.05.03 |
Formulary
|
NICE TA633 - Ustekinumab for treating moderately to severely active ulcerative colitis |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severley active ulcerative colitis |
Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |